Keylika said it was hacked; emails were down and the website was gone, indicating a temporary operational disruption.
SourceRedefining the Standard of Care for Iron Deficiency Anemia
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Keylika is a Walnut Creek biotech/biopharma startup building metal-based drug discovery plus delivery technology, best known for an iron-deficiency patch intended to deliver iron through the cheek/skin and avoid GI side effects and IV-infusion drawbacks.
Primary product
NistuFe / Riron, a wearable iron patch for iron deficiency anemia (IDA)
Founded
2022
Headquarters
Walnut Creek, California, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Drug discovery and drug delivery; metallodrug therapeutics
Offices
0 jobs at Keylika
Check back later for new openings
Business model
Stage
seed
Total raised
$500K
Latest round
Seed · Aug 2022
Latest amount
$500K
Aug 2022 · Y Combinator
Investors
Founder-led, science-heavy, stealthy, and scrappy; public posts emphasize patient impact, sustainability, and a default-alive/bootstrapped mindset.
Differentiators
Technology
Customers
Competitors
Keylika said it was hacked; emails were down and the website was gone, indicating a temporary operational disruption.
SourceLinkedIn post · Jun 2026
Keylika says Riron delivers 45 mg of elemental iron in under 10 minutes through the cheek and frames the product in terms of carbon-footprint reduction.
Entrepreneur APAC · Apr 2025
Profiles Keylika’s buccal patch, KEYPaxtek™, preclinical evidence, and the company’s Bakar Labs acceptance.
Arabian Business · Apr 2025
Covers Keylika’s buccal patch approach, KEYPaxtek™, preclinical hamster results, Bakar Labs involvement, and potential pharma partnerships.
LinkedIn post · Oct 2024
Company announcement that Keylika closed its first pilot deal with a major hematology biopharma company to advance its buccal iron delivery.
IBTimes · Apr 2024
Early coverage of Keylika’s iron patch concept, founding team, and preclinical progress toward clinical testing.